Table 6.
Inconsistency evaluation of enrolled studies.
| Comparison | Number of Studies | NMA | Direct | Indirect | Difference between Direct and Indirect Comparison |
Lower Limit of 95% CI | Upper Limit of 95% CI | p Value |
|---|---|---|---|---|---|---|---|---|
| Bimekizumab: Adalimumab |
1 | −0.00118 | −0.05449 | 0.408884 | −0.46337 | −1.76591 | 0.839167 | 0.485648 |
| Bimekizumab: Placebo | 1 | 0.581662 | 0.820981 | 0.480765 | 0.340215 | −0.61613 | 1.29656 | 0.485648 |
| Placebo: Secukinumab q4w | 2 | −0.30195 | −0.29957 | −1.60429 | 1.304712 | −3.15112 | 5.76054 | 0.566037 |
| Secukinumab q2w: Secukinumab q4w |
2 | −0.01153 | −0.00972 | −1.50507 | 1.495344 | −3.30894 | 6.299623 | 0.541833 |